Documente Academic
Documente Profesional
Documente Cultură
Schattauer 2012
Review Article
of Thrombosis and Haemostasis, Leiden University Medical Center, Leiden, The Netherlands; 2University of Birmingham Centre for Cardiovascular Sciences, City
Hospital, Birmingham, UK; 3Department of Neurology, University Hospital Essen, Essen, Germany; 4Global Clinical Development and Medical Affairs, Boehringer Ingelheim GmbH
& Co. KG, Ingelheim, Germany, 5Department of CardioMetabolic Disease Research, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany
Summary
Dabigatran etexilate is a new oral anticoagulant recently approved in
Europe for the prevention of stroke or systemic embolism in adult patients with non-valvular atrial fibrillation (AF) and at least one risk factor for stroke. With a fast onset of action and a predictable anticoagulant effect obviating the need for coagulation monitoring, dabigatran
etexilate offers practical advantages over vitamin K antagonists in clinical practice. However, clinicians may have questions about practical aspects of dabigatran etexilate use including monitoring anticoagulant
Correspondence to:
Menno V. Huisman
Department of Thrombosis and Haemostasis
Leiden University Medical Center, Leiden, Netherlands
Tel.: +31 752 62085, Fax: +31 71 5248140
E-mail: M.V.Huisman@lumc.nl
efficacy, interruption for surgical or invasive procedures and management of bleeding. This review article aims to address these concerns
and provide guidance on the use of dabigatran etexilate in special situations, such as acute coronary syndromes and cardiac revascularisation. In addition, cut-off values for different coagulation assay results
associated with an increased risk of bleeding are given.
Keywords
Dabigatran, atrial fibrillation, oral anticoagulant, bleeding
Note: The editorial process for this article was fully handled by Prof. Christian
Weber, Editor-in-Chief.
Introduction
Dose selection
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia (1), which if untreated is a major risk factor for stroke.
Extensive evidence from randomised trials supports the value of
vitamin K antagonists (VKAs) in reducing the risk of stroke by
about two thirds, even among elderly AF patients, who are at
higher risk (2, 3). However, practical limitations may lead to wide
variation in VKA use (4), as well as patient-related issues with adherence and convenience.
Dabigatran etexilate (hereafter referred to as dabigatran) is the
first oral direct thrombin inhibitor approved for the prevention of
stroke and systemic embolism in patients with non-valvular AF
and one or more risk factors (Fig. 1) (5, 6). The efficacy and
safety profile of dabigatran, demonstrated by the RE-LY trial (7, 8)
(Fig. 2), together with practical advantages over VKAs (see
Table 1), have led to its rapid uptake in clinical practice. However, there may be some areas of uncertainty in everyday clinical
practice, which this article aims to address. We focus on dosing
guidelines applicable to patients treated in Europe.
Huisman et al. Dabigatran a new oral anticoagulant for use in patients with AF
Switching treatment
A potential cause for concern among clinicians is in switching patients between different anticoagulant treatments. Suggested approaches are summarised in Table 3. If switching a patient from
Figure 1: Clinical flowchart for the use of dabigatran for stroke prea
AF is also associated with a high risk of bleeding (1, 56). d110 mg bid dose
recommended in patients taking verapamil, irrespective of age or renal function. 110 mg bid dose can be considered in patients with associated gastritis, oesophagitis or gastroesophageal reflux, irrespective of age or renal function. CrCL, Creatinine clearance; EU, European Union; NYHA, New York Heart
Association.
Schattauer 2012
839
840
Huisman et al. Dabigatran a new oral anticoagulant for use in patients with AF
VKAs
Dabigatran
Onset of action
Rapid (2 hours)
Offset of action
Dosing
Individualised
Fixed dose
Dose adjustment
Frequent
Rare
Monitoring
Interaction
No interaction
Drug interactions
Frequent
Few
Table 1: Limitations of
vitamin K antagonists
(VKA) in comparison
with dabigatran.
Schattauer 2012
Huisman et al. Dabigatran a new oral anticoagulant for use in patients with AF
ent test reagents (15). A trough aPTT >80 seconds (s) (or 2- to
3-fold of baseline value) is associated with a higher risk of bleeding
(5, 12). The TT is a more sensitive test and is significantly raised at
therapeutic doses and thus a normal TT or aPTT measurement indicates no clinically relevant anticoagulant effect of dabigatran.
Once again, there is some variability depending on the coagulometer and the thrombin reagent used for the measurement.
Demographic
Age 75 years
Major:
Moderate renal impairment (CrCL 3050 ml/
min)
P-gp inhibitor co-medication
Minor:
Low body weight (<50 kg)
Quantitative measurement
Conversion
For special patient populations requiring a reduced 110 mg bid dose, see Figure 1. ASA, acetylsalicylic acid; CrCL, Creatinine clearance; P-gp, P-glycoprotein; GI, gastrointestinal; ICH, intracranial haemorrhage; NSAID, non-steroidal
anti-inflammatory drug.
cedures. Longer delays may be needed for patients with a high bleeding risk including those undergoing major surgery, spinal puncture,
or placement of a spinal or epidural catheter or port.
Start dabigatran at the same time or up to 2 hours before the next parenteral drug dose. For
continuous infusions of parenteral drugs, start dabigatran at the time of discontinuation of
the continuous infusion.
aBecause
dabigatran may contribute to an elevated INR, the INR will better reflect the effect of the VKA after dabigatran has been
stopped for at least 2 days; bApplies to patients treated in the US and for patients in whom the CrCL drops below 30 mL/min. CrCL,
Creatinine clearance; h, hours; INR, International normalised ratio; VKA, vitamin K antagonists.
Schattauer 2012
841
842
Huisman et al. Dabigatran a new oral anticoagulant for use in patients with AF
Table 4: Anticoagulation measurement for dabigatran in patients administered 150 mg twice-daily for AFa.
Test
Increased risk of
bleeding
Expected value at
peak concentration
(2 h post dose)
aPTT
>80 s at trough
> 23 x baseline value
(23 x baseline value)
>65 s at trough
INR
Not applicableb
ECT
34 x baseline value
3 x baseline value
aEvidence
Re-starting dabigatran
Re-initiation of dabigatran following completion of surgery depends on the nature of the surgery, the urgency for restarting
thromboprophylaxis and the haemostatic state of the patient.
Where wound haemostasis is satisfactory, dabigatran can generally
be re-started with a single capsule (110 mg or 150 mg depending
Renal function
(CrCL in ml/min)
Estimated half-life
(hours)
High
bleeding riska
80
13
24 h before
2 days before
50 to <80
15
12 days before
23 days before
30 to <50
18
4 days before
aTypes
of surgery associated with a high risk of bleeding (or major surgery where complete haemostasis may be required) including
but not limited to cardiac surgery, neurosurgery, abdominal surgery, or surgeries involving a major organ. Other procedures such as
spinal anaesthesia may also require complete haemostatic function. h, hour.
Schattauer 2012
Huisman et al. Dabigatran a new oral anticoagulant for use in patients with AF
lation reversal may be due to the assays used to test this. Further
support for this comes from preclinical models where it was shown
that the lack of reversal of anticoagulation does not predict a lack
of bleeding reversal (24).
The use of platelet concentrates may be considered where
thrombocytopenia is present or long-acting antiplatelet drugs (e.g.
aspirin, clopidogrel) have been used. The low plasma protein binding of dabigatran (35%), suggests that dialysis may be useful although there is only limited experience with this (12). If dialysis is
not possible, constant haemoperfusion might also be applicable,
although, once again, there is no clinical experience with this approach.
Managing overdose
In vitro studies show that dabigatran is adsorbed by activated charcoal therapy (12). Although this has not been tested in vivo, a reasonable approach would be to administer charcoal within 12 h of
intake (overdose) to limit or prevent absorption in the gastrointestinal tract. Beyond 2 h use of charcoal is not useful. Haemoperfusion over a charcoal filter has also been suggested as a possible approach (25, 26), but has not been tested clinically.
Special situations
Thrombolysis in patients with acute ischaemic stroke
In the setting of acute ischaemic stroke, intravenous administration of recombinant tissue plasminogen activator (rtPA) is
proven if given to eligible patients within 4.5 h of symptom onset
(27). Warfarin-treated patients with stroke are not considered eligible for thrombolysis unless the INR 1.7, although an increased
risk of symptomatic intracerebral haemorrhage after thrombolytic
treatment has been reported even in those with subtherapeutic
INR levels (28). The use of thrombolysis in patients receiving concurrent dabigatran has not been studied and may increase the risk
of bleeding (5). There are few anecdotal reports. De Smedt et al. reported successful use of rtPA in a patient 4.5 h after onset of an ischaemic stroke and 7 h after receiving dabigatran (29). Matute et
al. (30) reported use of tPA 15 h after dabigatran when plasma concentration of dabigatran was low and aPTT was normal, suggesting absence of anticoagulant effect, which could have favoured the
absence of complications. In both of the above cases anticoagulation tests suggested a low risk of bleeding.
In patients who are considered possible candidates for thrombolysis, measurement of the aPTT, TT, or ECT are appropriate initial tests. A normal result from one of these assays generally indicates that the risk of bleeding is low, although there is also the
possibility that one or more doses of dabigatran may have been
missed. Since the INR is insensitive to dabigatran, a recommendation based on INR is not useful. Whether thrombectomy with
Schattauer 2012
843
844
Huisman et al. Dabigatran a new oral anticoagulant for use in patients with AF
Schattauer 2012
Huisman et al. Dabigatran a new oral anticoagulant for use in patients with AF
Dabigatran has a low potential for drug interactions. Dabigatran does not interact with the cytochrome P450 system. The
main clinically relevant interaction is with drugs that inhibit the
P-gp efflux transporter as the prodrug (dabigatran etexilate) is a
substrate. Thus, plasma concentrations of dabigatran are increased
when given with strong P-gp inhibitors such as amiodarone, verapamil and ketoconazole (5), and reduced when given with potent
inducers such as rifampicin, carbamazepine or phenytoin. Data
from RE-LY indicate that co-administration of P-gp inhibitors
(mainly amiodarone or verapamil) resulted in modest increases in
dabigatran plasma concentrations (12% overall increase) compared with that observed in healthy volunteer studies (49). Further,
the combination of P-gp inhibitors with dabigatran did not influence the overall benefits of dabigatran for stroke prevention,
major bleeding events or intracranial haemorrhage relative to warfarin. In view of the relatively small increases in exposure, dose
modification is not required when dabigatran is administered with
amiodarone or quinidine. However, in the European Union, when
co-administered with verapamil, a reduced dose of dabigatran 110
mg bid is recommended. Co-prescription with a PPI such as pantoprazole may slightly reduce dabigatran exposure and peak concentrations although these effects are not likely to reduce the efficacy of dabigatran. In RE-LY, use of PPIs decreased exposure by
12.5% with no impact on efficacy outcomes (50). Table 6 provides guidance for the use of dabigatran in conjunction with other
drugs based on the European prescribing guidelines (5).
Caution is recommended if considering co-administration of
dabigatran with other anticoagulants or antiplatelet agents due to
the increased risk of bleeding. Among patients receiving concomitant aspirin or clopidogrel in RE-LY, there was an increased risk of
major bleeding (HR 1.76, 95% CI 1.552.00), which was similar for
dabigatran 110 mg, 150 mg or warfarin (51). Data are lacking concerning the use of dabigatran in conjunction with new antiplatelet
treatments such as prasugrel and ticagrelor.
Practical aspects
Dabigatran etexilate capsules should be swallowed whole as breaking, chewing or emptying the contents can increase oral bioavailability and exposure by up to 75% (5). Once the medication bottle
has been opened, the capsules must be used within 120 days as they
are susceptible to humidity (6).
Compliance with twice-daily dosing is important and should be
addressed by patient education. Patients who miss a dose of dabigatran can take the dose up to 6 h before the next scheduled dose. If
this is not possible, the missed dose should be omitted. Patients
should not take a double dose to compensate for missed individual
doses. Clinicians should advise their patients about how to look for
signs of abnormal bleeding (such as epistaxis, gingival haemorrhage, subcutaneous haemorrhage, haematuria, or bloody
stools) and to call them immediately if such episodes develop.
Table 6: Guidance for use of dabigatran with other drugs (as per EU
label) (5).
Drug interactions and
dosing recommendation
No adjustment required
Atorvastatin
18%
Diclofenac
No effect
Pantoprazole
30%a
Clopidogrel
3040%a
Digoxin
No effect
Verapamil
50% a
Amiodarone
60% a
Clarithromycin
19% a
Not recommended
Dronedarone
100%a (58)
Rifampicin
67%a
Carbamazepine, phenytoin
(% not reported)
Protease inhibitors
(e.g. ritonavir, tipranavir,
nelfinavir and saquinavir)
Contraindicated
150%a
Systemic ketoconazole
Conclusions
Very clearly, many questions remain, and the present review article
nicely complements a recent position document from the Italian
Federation of Thrombosis Centers (FCSA) dealing with the use of
the new oral anticoagulants (52). The latter have clearly changed
our approach to thromboprophylaxis (53), so that in AF, effective
stroke prevention with new oral anticoagulants such as dabigatran
can be offered to patients with one or more stroke risk factors (54,
55).
Schattauer 2012
845
846
Huisman et al. Dabigatran a new oral anticoagulant for use in patients with AF
Conflicts of interest
References
1. Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European
Society of Cardiology (ESC). Eur Heart J 2010; 31: 23692429.
2. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med
2007; 146: 857867.
3. Mant J, Hobbs FD, Fletcher K, et al. Warfarin versus aspirin for stroke prevention
in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled
trial. Lancet 2007; 370: 493503.
4. Dewilde S, Carey IM, Emmas C, et al. Trends in the prevalence of diagnosed atrial
fibrillation, its treatment with anticoagulation and predictors of such treatment
in UK primary care. Heart 2006; 92: 10641070.
5. European Medicines Agency. Pradaxa. Summary of Product Characteristics. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Prod
uct_Information/human/000829/WC500041059.pdf. Accessed, 25 November 2011.
6. U.S. Food and Drug Administration Pradaxa Prescribing Information. Nov,
2011. Available at: http://www.pradaxa.com/. Accessed, 25 November 2011.
7. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients
with atrial fibrillation. N Engl J Med 2009; 361: 11391151.
8. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Newly identified events in the RE-LY
trial. N Engl J Med 2010; 363: 18751876.
9. Blech S, Ebner T, Ludwig-Schwellinger E, et al. The metabolism and disposition of
the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos
2008; 36: 386399.
10. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 3141.
11. 11. Legrand M, Mateo J, Aribaud A, et al. The use of dabigatran in elderly patients.
Arch Intern Med 2011; 171: 12851286.
12. van Ryn J, Stangier J, Haertter S, et al. Dabigatran etexilate a novel, reversible,
oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal
of anticoagulant activity. Thromb Haemost 2010; 103: 111611127.
13. Baruch L, Sherman O. Potential inaccuracy of Point-of-Care INR in dabigatrantreated patients. Ann Pharmacother 2011; 45: e40.
14. van Ryn J, Baruch L, Clemens A. Interpretation of point-of-care INR results in patients treated with dabigatran. Am J Med 2012, in press.
15. Lindahl TL, Baghaei F, Blixter IF, et al. Effects of the oral, direct thrombin inhibitor
dabigatran on five common coagulation assays. Thromb Haemost 2011; 105:
371378.
16. Stangier J, Feuring M. Using the HEMOCLOT direct thrombin inhibitor assay to
determine plasma concentrations of dabigatran. Blood Coagul Fibrinolysis 2012;
epub ahead of print.
17. European Medicines Agency. Committee for Medicinal Products for Human Use
(CHMP) Assessment Report for Pradaxa. 9 June 2011. Available from http://www.
ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/000829/WC500110875.pdf. Accessed, 24 November
2011.
18. Stangier J, Rathgen K, Sthle H, et al. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label,
parallel-group, single-centre study. Clin Pharmacokinet 2010; 49: 259268.
19. van Ryn J, Litzenburger T, Waterman A, et al. Dabigatran anticoagulant activity is
neutralized by an antibody selective to dabigatran in in vitro and in vivo models
(abstract). J Am Coll Cardiol 2011; 57 (Suppl 1): E1130.
20. Lu G, Deguzman FR, Karbarz MJ, et al. Reversal of rivaroxaban mediated anticoagulation in animal models by a recombinant antidote protein (r-Antidote,
PRT064445) (Abstract 3712). Eur Heart J 2011; 32: 640641.
21. Zeitler SH, Pragst I, Doerr B, et al. Beriplex P/N restores haemostasis after dabigatran overdosing in an acute rabbit bleeding model (abstract 1023). 16th World
Congress on Heart Disease, Annual Scientific Sessions 2011, Vancouver, BC, Canada, July 2326, 2011.
22. Eerenberg ES, Kamphuisen PW, Sijpkens MK, et al. Reversal of rivaroxaban and
dabigatran by prothrombin complex concentrate: A randomized, placebo-controlled, crossover study in healthy subjects. Circulation 2011; 124: 15731579.
23. CSL Behring Canada Inc. Product monograph Beriplex P/N (Human prothrombin complex), Nov 5, 2010. Available at: http://www.cslbehring.ca/
docs/17/83/Beriplex_NC134547_eng_app5nov10-ar.pdf. Accessed, 24 November 2011.
24. van Ryn J, Schurer J, Kink-Eiband M, et al. The successful reversal of dabigatraninduced bleeding by coagulation factor concentrates in a rat tail bleeding model
do not correlate with ex vivo markers of anticoagulation (Abstract 2316). Blood
2011; 118.
25. van Ryn J, Neubauer M, Flieg R, et al. Successful removal of dabigatran in flowing
blood with an activated charcoal hemoperfusion column in an in vitro test system
(abstract P485). Pathophysiol Haemost Thromb 2010; 57 (Suppl 1): A94.
26. Hankey GJ, Eikelboom JW. Dabigatran etexilate: a new oral thrombin inhibitor.
Circulation 2011; 123: 14361450.
27. Adams HP Jr, del Zoppo G, Alberts MJ, et al. Guidelines for the early management
of adults with ischemic stroke: a guideline from the American Heart Association/
American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary
Working Groups: The American Academy of Neurology affirms the value of this
guideline as an educational tool for neurologists. Circulation 2007; 115:
e478-e534.
28. Seet RC, Zhang Y, Moore SA, et al. Subtherapeutic international normalized ratio
in warfarin-treated patients increases the risk for symptomatic intracerebral
hemorrhage after intravenous thrombolysis. Stroke 2011; 42: 23332335.
29. De Smedt A, De Raedt S, Nieboer K, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator in a stroke patient treated with dabigatran.
Cerebrovasc Dis 2010; 30: 533534.
30. Matute MC, Guillan M, Garcia-Caldentey J, et al. Thrombolysis treatment for
acute ischaemic stroke in a patient on treatment with dabigatran. Thromb Haemost 2011; 106:178179.
31. Weimar C, Hohnloser SH, Eikelboom JW, et al. Preventing cardioembolic stroke
in atrial fibrillation with dabigatran. Curr Neurol Neurosci Rep 2011; epub ahead
of print.
32. Leebeek FWG, de Maat MP, Jones R, et al. Randomized, open-label, dose-ranging
study of dabigatran, a novel, oral, direct thrombin inhibitor, in elective PCI (the
D-fine study) (abstract O-TH-032). J Thromb Haemost 2011; 9 (Suppl 2): 731.
33. Lip GY, Huber K, Andreotti F, et al. European Society of Cardiology Working
Group on Thrombosis. Management of antithrombotic therapy in atrial fibril-
Schattauer 2012
Huisman et al. Dabigatran a new oral anticoagulant for use in patients with AF
lation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary intervention/ stenting. Thromb Haemost 2010; 103: 1328.
34. Faxon DP, Eikelboom JW, Berger PB, et al. Consensus Document: Antithrombotic
therapy in patients with atrial fibrillation undergoing coronary stenting. A NorthAmerican perspective. Thromb Haemost 2011; 106: 572584.
35. Eikelboom JW, Wallentin L, Connolly SJ, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: An analysis of the Randomized Evaluation of Long-term anticoagulant
Therapy (RE-LY) Trial. Circulation 2011; 123: 23632372.
36. Nagarakanti R, Ezekowitz MD, Oldgren J, et al. Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion.
Circulation 2011; 123: 131136.
37. Winkle RA, Mead RH, Engel G, et al. The use of dabigatran immediately after atrial fibrillation ablation. J Cardiovasc Electrophysiol 2011; epub ahead of print.
38. Blanc JJ, Almendral J, Brignole M, et al. Scientific Initiatives Committee of the
European Heart Rhythm Association. Consensus document on antithrombotic
therapy in the setting of electrophysiological procedures. Europace 2008; 10:
513527.
39. Verma A, Macle L, Cox J, at el. Canadian Cardiovascular Society atrial fibrillation
guidelines 2010: catheter ablation for atrial fibrillation/atrial flutter. Can J Cardiol
2011; 27: 6066.
40. Maegdefessel L, Linde T, Krapiec F, et al. In vitro comparison of dabigatran, unfractionated heparin, and low-molecular-weight heparin in preventing thrombus
formation on mechanical heart valves. Thromb Res 2010; 126: e196-e200.
41. McKellar SH, Abel S, Camp CL, et al. Effectiveness of dabigatran etexilate for
thromboprophylaxis of mechanical heart valves. J Thorac Cardiovasc Surg 2011;
141: 14101416.
42. RE-ALIGN: A randomised, phase II study to evaluate the safety of oral dabigatran
etexilate in patients after heart valve replacement. ClinicalTrials.gov Identifier:
NCT01452347. Accessed at http://www.clinicaltrials.gov.
43. Boehringer Ingelheim. Advisory Committee Briefing Document. Available from:
www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials
Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM226009.pdf.
Accessed, 27 November 2011.
44. Diener HC, Grond M, Rther J, et al. Dabigatran for stroke prevention in patients
with TIA or ischaemic stroke and atrial fibrillation: Practical apects. Akt Neurol
2011; 38: 261266.
45. Hohnloser SH, Oldgren J, Yang S, Wallentin L, Ezekowitz M, Reilly P, et al. Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran
or warfarin in the RE-LY trial. Circulation 2012; epub ahead of print.
46. Raju NC, Hankey GJ. Dabigatran etexilate in people with atrial fibrillation. Br
Med J 2010; 341: c3784.
47. Uchino K, Hernandez AV. Dabigatran association with higher risk of acute coronary events: Meta-analysis of noninferiority randomized controlled trials. Arch Intern Med 2012; epub ahead of print.
48. Kajubi SK. Additional monitoring tools to improve the quality of anticoagulation
management. Arch Intern Med 2000; 160: 3006.
49. Reilly PA, Conrad CA, Faaij RA, et al. Concomitant use of P-glycoprotein inhibitors with dabigatran or warfarin in the RE-LY trial (abstract 129). Eur Heart
J 2011; 32 (Suppl 1): 6.
50. U.S. Food and Drug Administration FDA Briefing Information, Dabigatran Etexilate Mesylate Capsules, for the September 20, 2010 Meeting of the Cardiovascular and Renal Drugs Advisory Committee. Oct 19th, 2010. Available at:
http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeeting
Materials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/
UCM247244.
pdf. Accessed, 24 November 2011.
51. Dans AM, Ezekowitz M, Wallentin L, et al. Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-term
Anticoagulation Therapy (RE-LY) trial (abstract 1161). Eur Heart J 2011; 32
(Suppl 1): 6.
52. Pengo V, Crippa L, Falanga A, et al. Questions and answers on the use of dabigatran and perpectives on the use of other new oral anticoagulants in patients with
atrial fibrillation. A consensus document of the Italian Federation of Thrombosis
Centers (FCSA). Thromb Haemost 2011;106: 868876.
53. Ahrens I, Lip GY, Peter K. New oral anticoagulant drugs in cardiovascular disease.
Thromb Haemost 2010;104: 4960.
54. Lip GY. Anticoagulation therapy and the risk of stroke in patients with atrial fibrillation at 'moderate risk' [CHADS2 score=1]: simplifying stroke risk assessment and thromboprophylaxis in real-life clinical practice. Thromb Haemost
2010; 103: 683685.
55. Gorin L, Fauchier L, Nonin E, et al. Antithrombotic treatment and the risk of
death and stroke in patients with atrial fibrillation and a CHADS2 score=1.
Thromb Haemost 2010; 103: 83340.
56. Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly score (HAS-BLED) to
assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro
Heart Survey. Chest 2010; 138: 10931100.
57. Eriksson BI, Dahl OE, Huo MH, et al. Oral dabigatran versus enoxaparin for
thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II). A
randomised, double-blind, non-inferiority trial. Thromb Haemost 2011; 105:
721729.
58. Brunet A, Hermabessiere S, Benain X. Pharmacokinetic and pharmacodynamic
interaction of dronedarone and dabigatran in healthy subjects (abstract P3566).
Eur Heart J 2011; 32 (Suppl 1): 618619.
Schattauer 2012
847